AWH - Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024 | Benzinga
- Aspira management will be available for meetings in San Francisco (January 8-10, 2024)
AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or "the Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan's Healthcare Conference Week 2024. Nicole Sandford, President and Chief Executive Officer, in addition to Torsten Hombeck, Ph.D., Chief Financial Officer from the management team will be in attendance at the following corporate access and partnering events:
Upcoming Corporate Access Event Participation
| 12th Annual LifeSci Partners Corporate Access Event 2024 |
| Date: |
| January 8-9, 2024 |
| Location: |
| Beacon Grand Hotel (formerly the Sir Francis Drake Hotel) |
For partnering and institutional one-on-one meeting requests please register via the following link: https://lifescievents.com/event/cae2024/
| H.C. Wainwright & Co. Hosted Investor Meetings |
| Date: |
| January 10, 2024 |
| Location: |
| Beacon Grand Hotel (formerly the Sir Francis Drake Hotel) |
For partnering and institutional one-on-one meeting requests please contact your representative at H.C. Wainwright & Co.
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is transforming women's gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuiteSM, which includes OvaWatchSM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative ...